Q&A With Paulo Fontura From Roche: Ocrelizumab Shows First Signs of Promise For Patients With Primary Progressive Multiple Sclerosis

Even as more medications are developed for relapsing remitting multiple sclerosis patients those with the primary progressive form have been left waiting for news on their condition. According to recent studies the first step in that process may soon be coming to the market.

Paulo Fontura, MD, PhD, the Global Head of Clinical Development for Neuroscience at Roche discussed the development of Ocrelizumab and what it can mean for patient care during the ECTRIMS conference in Barcelona.

Recent studies conducted involving a medication for multiple sclerosis showed promise not only for the relapsing remitting form of the disease but the primary progressive form as well.